Levosulpiride (S)-(-)-舒必利
CAS 23672-07-3 MFCD00055220
化学结构图
SMILES: CCN1CCC[C@H]1CNC(=O)C1=CC(=CC=C1OC)S(N)(=O)=O
化学属性
| Mol. Formula | C15H23N3O4S |
|---|---|
| Mol. Weight | 341 |
| Melting Point | 185-189 |
别名和识别编码
| Chemical Name | Levosulpiride |
|---|---|
| CAS Number | 23672-07-3 |
| Synonym | (S)-(-)-Sulpiride, (S)-N-[(1-Ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide Levosulpiride Levosulpiride (S)-(-)-止呕灵 (S)-5-氨基磺酰基-N-[(1-乙基-2-吡咯烷基)甲基]-2-甲氧基苯甲酰胺 (S)-5-氨基磺酰基-N-[(1-乙基-2-吡咯烷基)甲基]-2-甲氧基苯甲酰胺 左舒必利 (S)-N-[(1-Ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide Levosulpiride Levosulpiride |
| MDL Number | MFCD00055220 |
| PubChem Substance ID | 135726922 |
| Chemical Name Translation | (S)-(-)-舒必利 |
| Reaxys-RN | 3563418 |
| Merck Number | 8989 |
| Beilstein Registry Number | 3563418 |
| Wiswesser Line Notation | T5NTJ A2 B1MVR BO1 DSZW |
| LabNetwork Molecule ID | LN00193436 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Pharmaceuticals
- {SNA} Anta
- Sulfur & Selenium Compounds
- Chiral Reagents
- Heterocycles
- {SA} Antagonists, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Biochemicals and Reagents, Cell Biology, Cell Signaling and Neuroscience, Dopaminargics - Antagonists, Dopaminergics, GPCR Modulators, GPCR Proteins, Modulators and Antibodies, Membrane Prot
产品应用
- Dopamine D2 and D3-receptor antagonist. Antipsychotic; antidepressant; antiemetic.
相关文献及参考
- Pitre, D., et al.: Anal. Profiles Drug Subs., 17, 607 (1988),
- Wagstaff, A.J., et al.: CNS Drugs, 2, 313 (1994),
安全信息
- P264 Wash hands thoroughly after handling. 处理后要彻底洗净双手。
- P270 Do not eat, drink or smoke when using this product. 使用本产品时不要吃东西，喝水或吸烟。
- P273 Avoid release to the environment. 避免释放到环境中。
- P301+P312
- P330 Rinse mouth. 漱口
- P391 Collect spillage. Hazardous to the aquatic environment 收集对水环境有危害的泄漏物。
- P501 Dispose of contents/container to..… 处理内容物/容器.....
- H303 May be harmfully swallowed 吞食可能有害
GHS Symbol
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 42 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 12,944,1987
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 170 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : EJMCA5 European Journal of Medicinal Chemistry--Chimie Therapeutique. (Editions Scientifiques Elsevier, 29 rue Buffon, F-75005, Paris, France) V.9- 1974- Volume(issue)/page/year: 17,437,1982
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 53 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 12,944,1987
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : >1500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 12,944,1987
京ICP备2020036287号